Jasper Therapeutics (JSPR) Current Assets (2019 - 2026)

Jasper Therapeutics has reported Current Assets for 8 years, with the latest figure at $11.6 million in Q2 2026.

• On a quarterly basis, Current Assets fell 73.07% year-over-year to $11.6 million in Q2 2026; TTM through Jun 2026 was $11.6 million, a 73.07% decrease from a year earlier, with the FY2025 full-year figure at $34.6 million, down 54.3% from the prior year.
• Current Assets was $11.6 million for Q2 2026 at Jasper Therapeutics, down from $34.6 million in the prior quarter.
• The five-year high for Current Assets was $132.5 million in Q1 2023, with the low at $11.6 million in Q2 2026.
• Average Current Assets over 5 years is $74.9 million, with a median of $73.8 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Current Assets soared 14863.81% in 2022, then plunged 73.07% in 2026.
• Over 5 years, Current Assets stood at $41.7 million in 2022, then soared by 113.12% to $88.9 million in 2023, then retreated by 14.76% to $75.8 million in 2024, then plunged by 54.3% to $34.6 million in 2025, then sank by 66.6% to $11.6 million in 2026.
• The last three Current Assets figures came in at $11.6 million (Q2 2026), $34.6 million (Q4 2025), and $54.6 million (Q3 2025), per Business Quant data.